Director/PDMR Shareholding

RNS Number : 8971D
Hikma Pharmaceuticals Plc
07 March 2022
 

 

Hikma Pharmaceuticals PLC - EIP B Vesting

LONDON, 7 March 2022: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 27 February 2020 under the 2014 Executive Incentive Plan ("EIP") Element B. The vesting process was completed on 4 March 2022.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 47,169

d)

Aggregated information

Volume

Price

 

Total

 

 

47,169

£0.00

£0.00

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Siggi Olafsson

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sigurdur Olafsson

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  20,298 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 32,850

 

Price(s): £19.57

Volume(s): 20,298

d)

Aggregated information

Volume

Price

 

Total

 

 

53,148

£19.57

£397,231.86

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 32,993

d)

Aggregated information

Volume

Price

 

Total

 

 

32,993

£0.00

£0.00

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 27,086

d)

Aggregated information

Volume

Price

 

Total

 

 

27,086

£0.00

£0.00

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 14,211

d)

Aggregated information

Volume

Price

 

Total

 

 

14,211

£0.00

£0.00

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 22,610

d)

Aggregated information

Volume

Price

 

Total

 

 

22,610

£0.00

£0.00

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 22,709

d)

Aggregated information

Volume

Price

 

Total

 

 

22,709

£0.00

£0.00

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Brian Hoffmann

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian Hoffmann

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B. 5,516 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 8,925

 

Price(s): £19.57

Volume(s): 5,516

d)

Aggregated information

Volume

Price

 

Total

 

 

14,441

£19.57

£107,948.12

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  5,550 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 6,199

 

Price(s): £19.57

Volume(s): 5,550

d)

Aggregated information

Volume

Price

 

Total

 

 

11,749

£19.57

£108,613.50

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Henriette Nielsen

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Henriette Nielsen

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  5,972 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 9,663

 

Price(s): £19.57

Volume(s): 5,972

d)

Aggregated information

Volume

Price

 

Total

 

 

15,635

£19.57

£116,872.04

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Shahin Fesharaki

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Shahin Fesharaki

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  2,961 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 4,791

 

Price(s): £19.57

Volume(s): 2,961

d)

Aggregated information

Volume

Price

 

Total

 

 

7,752

£19.57

£57,946.77

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Hussein Arkhagha

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hussein Arkhagha

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
28 February 2022 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 11,308

d)

Aggregated information

Volume

Price

 

Total

 

 

11,308

£0.00

£0.00

e)

Date of the transaction

4 March 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760

7 March 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBXGDXUXGDGDR
UK 100

Latest directors dealings